Dr. Timothy John Daskivich, MD

Dr. Daskivich practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Daskivich's NPI, 1225278211, was assigned on March 3, 2009. Dr. Daskivich graduated from Harvard Medical School in 2006. Dr. Daskivich's California license number on file is A103871.

Dr. Daskivich's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Daskivich's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. The medical group on file is Cedars-Sinai Medical Center. Dmand AI also links Dr. Daskivich to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Daskivich practices. Vendor and product names are available with a free account.

Urology is Dr. Daskivich's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Daskivich is board certified in urology by the American Board of Urology. Dr. Daskivich has a license on file in California.

Dmand AI lists enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney removal surgery, kidney stone disease, prostate cancer, prostate surgery and urinary endoscopy among the conditions Dr. Daskivich treats.

CMS data shows 527 Medicare services from Dr. Daskivich across 12 procedure codes in 2024, for 247 Medicare patients. Medicare paid $36,628 for them.

CMS counts 247 Medicare patients who saw Dr. Daskivich in 2024. The largest group is 65 to 74, with 145 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 17% are also on Medicaid. Their average risk score is 1.55, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Daskivich's median patient age at 72, with 9% women.

In 2024, Dr. Daskivich wrote 513 Medicare Part D claims for 144 patients. 82% of them were for generic drugs. CMS names the drug for 439 of them, across 10 drugs with 11 or more claims each, at $69,934 in total drug cost. In 2023, CMS named 432 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Daskivich for performance year 2024, reported as part of a group. Dr. Daskivich accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Daskivich as offering telehealth.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 14 papers to Dr. Daskivich, published from 2019 to 2025. 2025 was the busiest year, with 3. The most frequent topics are Prostatic Neoplasms. Dr. Daskivich's most frequent co-authors are John Thomas Leppert, MD, Christopher Lee Amling, FACS, MD and William Aronson, MD.

Dmand AI links Dr. Daskivich to 5 clinical trials. 1 is still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Patient Satisfaction. Cedars-Sinai Medical Center sponsors the most, 4.

CMS Open Payments shows 57 general payments to Dr. Daskivich from 9 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 79% of the total. Edap Technomed Inc paid the most, $27,234.

Dr. Daskivich graduated from Harvard Medical School in 2006.

Dr. Daskivich is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.